These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. Hiatt WR; Kaul S; Smith RJ N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603 [No Abstract] [Full Text] [Related]
6. FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on. Mullard A Nat Rev Drug Discov; 2018 Dec; 17(12):850-851. PubMed ID: 30443037 [No Abstract] [Full Text] [Related]
7. Cardiovascular effects of diabetes drugs: emerging from the dark ages. Nissen SE Ann Intern Med; 2012 Nov; 157(9):671-2. PubMed ID: 23128866 [No Abstract] [Full Text] [Related]
8. Prevalence of cardiovascular events in diabetic patients taking sulphonylureas: need for assessment. Rohra DK; Maheshwary AR; Gauba SS J Pak Med Assoc; 2007 Mar; 57(3):163. PubMed ID: 17432030 [No Abstract] [Full Text] [Related]
9. Cardiovascular trials and diabetes treatments: a regulatory maze. Matthews DR Diab Vasc Dis Res; 2012 Apr; 9(2):83-4. PubMed ID: 22419242 [No Abstract] [Full Text] [Related]
10. Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDA. Chong WH; Yanoff LB; Andraca-Carrera E; Thanh Hai M N Engl J Med; 2020 Sep; 383(13):1199-1202. PubMed ID: 32966719 [No Abstract] [Full Text] [Related]
11. [Glitazone - mailing no 1. In response to DMW 49/2007]. Traut V Dtsch Med Wochenschr; 2008 Feb; 133(6):261; author reply 262-3. PubMed ID: 18236356 [No Abstract] [Full Text] [Related]
12. [Glitazone - mailing no 3. In response to DMW 49/2007]. Gundel UF Dtsch Med Wochenschr; 2008 Feb; 133(6):261-2; author reply 262-3. PubMed ID: 18236354 [No Abstract] [Full Text] [Related]
13. [The influence of drugs used in the treatment of diabetes type 2 on the cardio-vascular risk]. Kern A; Zaleska M; Możeńska O; Bil J Wiad Lek; 2017; 70(4):827-833. PubMed ID: 29064812 [TBL] [Abstract][Full Text] [Related]